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Abstract: One of the major concerns of the 
pharmaceutical industry is the importance of the 
regulations which have to be fulfilled. These 
establish various requirements for processes and 
associated systems without defining the ways to 
achieve the expected compliance. Such regulatory 
requirements concern also computerized systems 
used for manufacturing-, laboratory-, distribution- or 
clinical study-related activities. 
After a short introduction to the pharmaceutical 
regulatory framework, this article will show the 
approach for achieving the regulatory compliance 
used within the industry, based on the 
recommendations promoted by the GAMP® Guide. 
Thereby, three key-topics will be presented: system 
life cycle, risk management and system testing. 
Keywords: computerized system validation, 
regulatory compliance, system life cycle, risk 
management, testing, GAMP® 
1. Introduction: “You’ll soon feel better! …” 
When we were sick as children, after being given 
some medicine, we often heard the sentence “You’ll 
soon feel better! …”. Indeed, in highly developed 
countries, medicinal products extend the life of 
humans by 16 years on average. At the same time, 
due to side effects, medicinal products reduce the 
life of humans by 37 minutes on average. [1] 
Unfortunately, in some third world countries, 10 to 
50% of all drugs which patients receive are 
counterfeits. This signifies that some of them are 
without any active ingredients and/or with harmful 
other ingredients. [1] 
The control of the market, with the help of 
regulations, inspections and testing in medicine 
control laboratories, makes the difference. The 
control of the market is as effective as it is focused 
on the risks associated with the products for the 
patients. 
The challenge for the pharmaceutical industry is to 
fulfil regulatory requirements and at the same time 
maintain an economic efficiency. 
2. Pharmaceutical Regulations 
2.1 Regulatory Agencies 
A regulatory agency is a national governmental 
authority which is responsible for the control of 
healthcare organizations regarding the correct 
consideration of national and, if appropriate, 
international standards. 
The goal is to protect the citizen, i.e. the patient’s 
health. 
Historically, the US Food and Drug Administration 
(US FDA) was the first to initiate the definition of the 
principles for software validation. Today, the major 
Agencies (incl. EMEA through the European 
Commission) establish such principles and related 
rules directly or via harmonisation working groups 
such as PIC/S. 
2.2 Regulatory inspections 
Regulatory agencies perform inspections of 
pharmaceutical organizations and their facilities on a 
regular basis. The inspection objectives are to 
control workflows, processes and systems in relation 
with a product. 
For this reason, computerized systems are inspected 
based on their impact on the product quality and 
safety. In this way the inspection focus on 
computerized system could be more or less strong. 
Since regulations define only requirements which 
have to be fulfilled by the pharmaceutical 
organizations without defining the ways to achieve 
the expected compliance, there is no absolute 
compliance standard.  
2.3 Principles 
The complex regulatory framework impacting 
pharmaceutical processes and equipment could be 
summarized in the following definition established by 
the US FDA in 1987: 
“Process validation is establishing documented 
evidence which provides a high degree of assurance 
that a specific process will consistently produce a 
product meeting its pre-determined specifications 
and quality attributes.” [2] 
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As consequence of this first definition, software 
validation is considered to be “confirmation by 
examination and provision of objective evidence that 
computer system specifications conform to user 
needs and intended uses, and that all requirements 
can be consistently fulfilled.” [3] 
2.4 Regulatory impact on computerized systems 
The consequence of the above mentioned principles 
is that every system involved in product-related 
processes must be validated. 
Various computerized systems are impacted by 
these requirements. There are for example: 
? Laboratory equipment used for: 
• Product development 
• Product quality control 
? Manufacturing equipment such as: 
• Automated production equipment 
• Infrastructure equipment (HVAC, water, …) 
? IT systems such as: 
• Clinical study applications 
• Document management systems 
• Manufacturing execution systems 
• Logistics systems 
Especially in the area of process control and 
laboratory automation, the range of impacted 
automation systems is very wide. This covers for 
example: 
?  Process control systems 
• Distributed control systems (DCS) 
• Programmable logic controllers (PLC) 
• Supervisory, control, and data acquisition 
systems (SCADA) 
? Automation devices 
• Sensors: measurement devices, etc. 
• Actuators: PID-controllers, motor controllers, 
etc. 
? Laboratory systems 
• pH-meters 
• laboratory scales 
• Chromatography instruments (HPLC, HPGC) 
• DNA sequencers 
• PCR-based systems. 
The challenge for the pharmaceutical organizations 
consists of achieving a consistent level of 
compliance based on the above mentioned 
principles for every impacted system.   
3. Computerized System Validation 
3.1 Validation in the daily business 
“Process validation is establishing documented 
evidence which provides a high degree of assurance 
that a specific process will consistently produce a 
product meeting its pre-determined specifications 
and quality attributes.” [2] 
This principle can be illustrated based on the 
following scheme: 
Predetermined specifications & quality attributes 
? User requirements specification (URS) 
? Functional specification (FS) 
? Design specification (DS) 
? etc. 
Predetermined quality attributes 
? Test specifications with expected results 
Consistently 
? Test specifications (against technical 
specifications, i.e. URS, FS, DS, …): 
• Module & integration tests 
• Installation qualification (IQ) 
• Operational qualification (OQ) 
• Performance qualification (PQ) 
• Factory and site acceptance tests 
(FAT, SAT) 
? Traceability matrix. 
The main objective of the validation is to provide 
evidence that requirements are fulfilled and that the 
system (or the process) is fit for purpose. 
3.2 How to fulfil regulatory requirements? 
Complying with regulations implies satisfying, among 
others, requirements such as: 
? To follow a prospective engineering approach 
? To specify what is expected 
? To define working processes 
? To control that processes are followed correctly 
? To test the system against the specifications 
? To document consistently the different 
engineering phases 
? To control changes 
? To have a control organization: 
• Quality Assurance. 
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Although computerized system validation (CSV) 
impacts computer systems as well as users, 
procedural controls and the environment, the 
following part of this document will discuss only the 
aspects of: 
? System life cycle 
? Risk management 
? System testing. 
3.3 System Life Cycle 
In order to work in a consistent manner, a well 
structured and formalized system life cycle (SLC) is 
necessary. 
Often, the SLC is reduced by covering only the 
development activities: “System Development Life 
Cycle” (SDLC). Although the development phase is 
very important regarding system quality as well as 
security and safety, regulatory compliance requires 
that a system should be developed and operated 
according to current good practice. 
3.3.1 System Development Life Cycle 
Regulations as well as industry standards do not 
prescribe any life cycle model. Nevertheless, the 
usual reference model is the “V Model” (see 
Figure 1). 
 
Figure 1: Reference “V Model” 
One of the major benefits of this representation is to 
highlight the strong relationship between “technical 
specifications” (left branch) and the corresponding 
“test specifications” (right branch). Because 
regulations request evidence that the system meets 
the requirements, it is essential for performing 
validation activities that tests are systematically 
defined as well as that every requirement is tested in 
an appropriate manner. 
Depending on the system complexity, the life cycle 
could be adapted and customized1. 
                                                          
1 Usually, the life cycle is binding and is defined in the system 
specific Validation Plan (or Qualification Plan). 
? The SDLC of a specifically developed system 
should describe every activity with an appropriate 
granularity and depth. In this case, the design 
specifications should describe software design as 
well as each software module. 
? By so called “Commercial Off-The-Shelf” systems 
(COTS), the SDLC includes little actual (software) 
implementation activities which are under the 
system owner’s direct responsibility. 
Regardless of the chosen approach, it is the 
responsibility of the system owner to ensure that 
development activities are performed according to 
the current good practice. For COTS systems as well 
as for sub-contracted development work, supplier 
audits are an efficient way for demonstrating supplier 
maturity. In case of deficiencies, corrective (and 
supporting) measures based on the observed 
weaknesses should be put in place and controlled 
during the project. 
Even if the V Model is widely used as the reference 
model for the development activities it does not 
assume that a sequential waterfall model has to be 
followed. An iterative approach of the development 
tasks is also acceptable. In such cases, each 
iteration should follow the V Model (specify, 
implement, test, report) and the entire development 
corresponds to a succession of several “Vs”. 
It is worth mentioning here that the approach 
recommended by the (IBM Rational) Unified Process 
satisfies both the requirements for a well formalized 
prospective workflow as well as an iterative 
methodology facilitating good progress control and 
risk management based on prototyping. 
3.3.2 Integral System Life Cycle 
At the end of the development, as soon as the 
system becomes operational and until its retirement, 
it is necessary to take into account the 
corresponding regulatory requirements. 
For this reason, a binding formalization of activities is 
indispensable. It concerns the following topics: 
? System access control 
• Physical and logical access control 
? Data management [9] 
• Backup and restore 
• Archiving and retrieval 
? Disaster recovery and business continuity 
? Change control and maintenance. 
At the time the system must be retired, it is also 
necessary to decommission the system with 
sufficient control: 
? To prove that the system worked correctly until 
the end 
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? To ensure the integrity of records which must be 
kept at least for regulatory purpose after the 
system is turned off. 
This Integral System Life Cycle is also called the 
“Spoon Model” due to its representation which is 
similar to a spoon (see Figure 2). 
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Figure 2: Spoon Model 
3.3.3 Life Cycle Requirements 
Regardless of the kind of specific life cycle activity, 
the following requirements must be fulfilled: 
? The activity must be achieved prospectively 
• Pre-defined operational procedures (SOP) 
• Pre-defined task schedule, if appropriate 
• Pre-defined controls and acceptance criteria 
• Pre-defined of behaviour in case of deviation 
? Activity as well as documentation must stay 
under change control based on formalized 
procedures 
? Procedures (SOP) must be exercised (especially 
SOPs which are rarely used, e.g. disaster 
recovery). 
Because process documentation is vital to 
demonstrate that the process and systems run 
accordingly to the specifications, data and especially 
record management are critical tasks. One objective 
of the CSV is to ensure the integrity of data and 
records. (See also [4], [5], [6] and further [7]) 
In addition to the regulatory agencies, which perform 
inspection to control healthcare organizations, 
controls, releases and audits are executed internally 
by the quality assurance (QA) department. Every 
SOP, every URS, every validation plan and report as 
well as every change request must be approved by 
QA. 
3.4 Risk management 
Since it is not possible and not cost-effective to test 
all functionality (and especially in combination with 
each other), it is necessary to follow a more 
pragmatic approach based on the identification of 
critical functions and process steps. The validation 
(incl. test) effort will be focused on the functionality 
identified as critical. 
3.4.1 Which risks? 
The criticality and finally the risk assessment should 
consider the following aspects and impacts: 
? Safety and security 
• Risk for people (safety) 
• Environmental risk (ecology) 
• Risk for plant and equipment (security) 
? Product related risks 
• Insufficient quality: the product does not meet 
the pre-defined quality attributes 
? Regulatory risks 
• Regulatory and/or legal requirements are not 
fulfilled correctly 
? Operational and business risk 
• Corporate reliability and reputation, ... 
3.4.2 Risk assessment 
Even regulatory agencies have endorsed a 
validation approach based on risk evaluation for a 
number of year, they do not prescribe or recommend 
any particular methodology regarding risk 
assessment and risk management. 
For this reason, the GAMP® Forum proposed in [8] a 
basic approach which can be easily enhanced with 
the help of more intensive methods like HAZOPS, 
HACCP, FMEA, or based on ISO/EN 14971:2002. 
After identification of the risk scenarios, the risk 
evaluation must consider for each scenario the 
following aspects (see also [8], Appendix M3): 
? Risk likelihood 
? Business impact 
? Probability of failure detection 
The business impact should be understood widely 
(covering safety, security, product quality and 
operational aspects incl. regulatory compliance). 
Based on the assessed criticality, risk mitigation 
measures should be defined, implemented and 
tested. Depending on the criticality, good 
engineering practices and, if needed, more intensive 
qualification work should be specified in order to 
ensure that the mitigation measures are correctly 
implemented, without producing additional (and un-
assessed) risks. (See also [10]) 
Finally, whatever the chosen risk evaluation method 
is, the risk management process must be formalized 
and the results have to be documented accurately. 
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3.5 System testing 
3.5.1 Objective 
The first and major objective of testing is: 
? To provide evidence that a system is fit for 
purpose, meeting user and business 
requirements. 
For this reason, every specification item, identified 
as critical regarding the validation state, needs to be 
tested formerly. 
3.5.2 When to test? 
According to the reference life cycle model, several 
test phases, achieving different goals, should be 
executed: 
? Acceptance tests 
• Software module tests & software module 
integration tests 
• Factory acceptance tests (FAT) 
• Site acceptance tests (SAT) 
? Qualification 
• Installation qualification (IQ) 
• Operational qualification (OQ) 
• Performance qualification (PQ). 
During the initial acceptance tests, the system 
design fitness should be demonstrated. 
During the qualification, the IQ should prove the 
correct installation of the system. Afterwards, OQ 
and PQ should demonstrate the fitness for purpose 
of the system. The PQ should support the final user 
acceptance of the system. 
3.5.3 How to test?  
Tests must occur based on formal test scripts. These 
have to be approved prior to beginning the testing. 
The test scripts are structured based on test cases. 
For each test case, it must be defined, amongst 
others: 
Test identification number (Test-ID) 
? Cross-reference to the related specification 
• e.g. Requirement or specification-ID 
? Test pre-requisites 
? Test method (& test data) 
? Expected test result 
? Test result 
? Test record 
? Test fulfilment statement 
• Passed/Failed 
? Date & signature of the tester 
• (Note: only for tests performed manually. For 
automated testing, a different formalism could 
be agreed). 
The test results must be consistently reproducible 
and the test records must be reviewed and 
approved. The basic principle is that tests must be 
performed and test records must be approved prior 
to the beginning of the next test phase unless a 
different procedure is agreed in the validation plan. 
Although the required test formalism could seem to 
be a little heavy, the regulations expect such 
formalism. 
Test consistency and reproducibility are the keys for 
providing “objective evidence that computer system 
specifications conform to user needs and intended 
uses, and that all requirements can be consistently 
fulfilled.” [3] 
4. Industry Standards 
Because regulations do not give any 
recommendation about the way to achieve 
compliance, regulated users2 need support 
regarding the possible and appropriate ways to 
achieve regulatory compliance and to maintain the 
computerized systems in a validated state. 
Already in the second half of the eighties, the 
pharmaceutical companies started to work together 
within the PMA CSVC on the elaboration of a 
guideline related to the Computer System Validation. 
At the beginning of the nineties, after several difficult 
inspections (so called “pivotal inspections”), several 
people, mostly coming from the industry, started the 
“GAMP® initiative”, initially to provide guidance for 
the suppliers of the pharmaceutical industry. 
After several years and versions, the GAMP® Guide 
([8]) is a recognized document within the healthcare 
sector for users, suppliers as well as regulators. 
The Guide is not binding and it is neither a regulation 
nor a norm. However the recommendations 
proposed by the GAMP® Forum represent a 
reasonable and well accepted way to meet 
regulatory requirements, even if other approaches 
are possible. 
Today, several “Good Practice Guides” develop 
specifically the concepts promoted in GAMP 4 ([8]) 
needing a particular focus, e.g.: 
? Validation of Process Control Systems 
? Validation of Laboratory Computerized Systems 
                                                          
2 ‘users’ (owners of the good practice computerised systems 
being inspected) are collectively referred to as ‘regulated 
users’ [7] 
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? IT Infrastructure Control and Compliance 
? Electronic Records and Signatures. 
The GAMP® Forum is now a technical subcommittee 
of ISPE. 
On the regulator’s side, international working groups 
have developed guidance for the inspectors. The 
guide PI 011-2 [7] edited by PIC/S is one of the 
major documents concerning computerized systems 
validation. 
5. Conclusion 
Compared to the situation 15 years ago, industry 
and regulators now have available valuable and 
mature guides and recommendations for achieving 
regulatory compliance. 
Although the formalism regarding processes and the 
documentation of activities is strong, the 
pharmaceutical industry has wide freedom to define 
the most appropriate approach to achieve 
compliance. 
Based on a few fundamental concepts and on a 
prospective approach to project management and 
engineering activities, the regulated user is able to 
choose the way how to fulfil regulatory requirements 
for its particular system. 
This is only possible if the life cycle for the 
development and operational phases are correctly 
formalized – based on an established quality 
management system – and if the existing risks are 
assessed consistently. 
Finally, nothing is possible without the presence of a 
QA organization which controls the application of the 
defined working approach and its conformity 
(compliance) with the organization QMS and 
applicable regulatory requirements 
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8. Glossary 
COTS Commercial Off-The-Shelf 
CSV Computerized System Validation 
CSVC Computer System Validation Committee (part 
of PMA) 
DCS Distributed Control System 
DNA Deoxyribo Nucleic Acid 
DS Design Specification 
EMEA European Agency for the Evaluation of 
Medicinal Products 
FAT Factory Acceptance Test 
FMEA Failure Mode Effect Analysis 
FS Functional Specification 
GAMP Good Automated Manufacturing Practice 
GxP Generic expression covering Good Clinical, 
Distribution, Laboratory and Manufacturing 
Practice 
HACCP Hazard Analysis and Critical Control Points 
Study 
HAZOPS Hazard Operability Study 
HPGC High Performance Gas Chromatograph 
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HPLC High Performance Liquid Chromatograph 
HVAC Heating Ventilation Air Conditioning 
IQ Installation Qualification 
ISPE International Society of Pharmaceutical 
Engineering 
OQ Operational Qualification 
PCR Polymerase Chain Reaction 
PIC/S Pharmaceutical Inspection Cooperation 
Scheme 
PLC Programmable Logic Controller 
PMA Pharmaceutical Manufacturers Association 
PQ Performance Qualification 
QA Quality Assurance 
QMS Quality Management System 
SAT Site Acceptance Test 
SCADA Supervisory, Control, and Data Acquisition 
system 
SDLC System Development Life Cycle 
SLC System Life Cycle 
SOP Standard Operating Procedure 
URS User Requirements Specification 
US FDA US Food and Drug Administration: Regulatory 
Agency in the USA (US government) 
9. Useful links 
? A white paper based on this document is 
available at the following address: 
• www.kereon.ch/wp 
? ISPE: Engineering Pharmaceutical Innovation 
• www.ispe.org 
? GAMP® Forum 
• www.ispe.org/gamp 
? PIC/S: Pharmaceutical Inspection Cooperation 
Scheme 
• www.picscheme.org 
? EMEA: European Agency for the Evaluation of 
Medicinal Products 
• www.emea.eu.int 
? European Commission 
• pharmacos.eudra.org 
? FDA: Food and Drug Administration 
• www.fda.gov 
• www.fda.gov/cder 
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